Skip to main content

Table 1 Patients’ clinical characteristics, pharmaceutical treatment and procedure time intervals

From: Assessment of myocardial salvage in patients with STEMI undergoing thrombolysis: ticagrelor versus clopidogrel

 

Clopidogrel n = 21

Ticagrelor n = 21

p-value

Males

17 (80.9%)

20 (95.2%)

ns

Females

4 (19%)

1 (4.7%)

ns

Age (years)

57.9 ± 7.04

53.71 ± 9.33

ns

Risk factors

 Hypertension

11 (52.3%)

9 (42.8%)

ns

 Dyslipidemia

7 (33.3%)

8 (38%)

ns

 Diabetes

7 (33.3%)

4 (19%)

ns

 Smokers

17 (80.9%)

18 (85.7%)

ns

Laboratory parameters

 Hematocrit (%)

44.6 ± 4.28

43.54 ± 2.92

ns

 Platelet count (K/μl)

276.4 ± 79.42

253 ± 81.07

ns

 Estimated glomerular filtration rate (ml/min)

110.8 (62–130.8)

95 (69.95–101)

ns

Time intervals

 Symptom-to-Needle time (hours)

2.33 (2–5.2)

1.92 (1.5–4.1)

ns

 Needle-to-Balloon time (hours)

33.25 ± 19.67

31.78 ± 20.27

ns

Successful thrombolysis

19/21 (90.4%)

20/21 (95.2%)

ns

Fibrinolytic agent used

 Tenecteplase

21 (100%)

21 (100%)

ns

Concomitant medications at inclusion

 Unfractionated heparin

1 (4.76%)

0 (0%)

ns

 Low-molecular-weight heparin

20 (95.2%)

21 (100%)

ns

 Aspirin

21 (100%)

21 (100%)

ns

 Statin

6 (28.57%)

5 (23.8%)

ns

 Beta-blocker

4 (19%)

3 (14.3%)

ns

 Nitroglycerine

7 (33.3%)

6 (28.5%)

ns

 Angiotensin converting enzyme/angiotensin receptor inhibitors

5 (23.8%)

7 (33.3%)

ns

Medication at discharge from hospital

 Aspirin

21 (100%)

21 (100%)

ns

 High dose Statin

21 (100%)

21 (100%)

ns

 Atorvastatin 40 or 80 mg

16 (76.2%)

14 (66.6%)

ns

 Rosuvastatin 20 or 40 mg

5 (23.8%)

7 (33.3%)

ns

 Beta-blockers

16 (76%)

17 (80%)

ns

 Angiotensin converting enzyme/angiotensin receptor inhibitors

18 (85.7%)

16 (76%)

ns

 Mineralocorticoid receptor antagonists

2 (9.5%)

3 (14.2%)

ns

  1. Data are presented as mean ± Standard Deviation, median (quartiles 1–3), or number and percentage of patients. p-values express comparison between the two groups (Clopidogrel versus Ticagrelor)